Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

ImmuPharma PLC

IMM
Current price
1.69 GBX +0.14 GBX (+9.03%)
Last closed 1.54 GBX
ISIN GB0033711010
Sector Healthcare
Industry Biotechnology
Exchange London Exchange
Capitalization 6 489 133 GBX
Yield for 12 month -8.65 %
1Y
3Y
5Y
10Y
15Y
IMM
21.11.2021 - 28.11.2021

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD. Its pre-clinical products include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations for serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection treatment. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom. Address: 1 Bartholomew Close, London, United Kingdom, EC1A 7BL

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

379.63 GBX

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

-3 505 333 GBX

Last Quarter

-3 505 333 GBX

Current Year

-3 768 567 GBX

Last Year

-11 780 844 GBX

Current Quarter

-3 505 333 GBX

Last Quarter

-3 505 333 GBX

Key Figures IMM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -3 031 709 GBX
Operating Margin TTM 2522.29 %
PE Ratio
Return On Assets TTM -57.18 %
PEG Ratio
Return On Equity TTM -163.24 %
Wall Street Target Price 379.63 GBX
Revenue TTM 70 105 GBX
Book Value 0.003 GBX
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 47.1 %
Dividend Yield
Gross Profit TTM 118 597 GBX
Earnings per share -0.01 GBX
Diluted Eps TTM -0.01 GBX
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IMM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

-93 %

Dividend History IMM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 14.12.2021
Forward Annual Dividend Yield
Last Split Factor 1:1
Payout Ratio
Last Split Date 17.08.2022
Dividend Date

Stock Valuation IMM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 73.6224
Price Sales TTM 60.7506
Enterprise Value EBITDA -0.9408
Price Book MRQ 2.4062

Financials IMM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators IMM

For 52 weeks

0.82 GBX 3.01 GBX
50 Day MA 1.71 GBX
Shares Short Prior Month
200 Day MA 1.83 GBX
Short Ratio
Shares Short
Short Percent